Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1078 • ACR Convergence 2024
Improving SLEDAI-2K Documentation for Childhood-Onset Systemic Lupus Erythematosus (cSLE) in a Pediatric Rheumatology Clinic Using Quality Improvement Methodology
Ivana Stojkic¹, Vinchelle Hardison¹, Fatima Barbar-Smiley², Mahmoud Kallash³, Hiren Patel³, Jonnie Lee Hughes³, James Gallop³, Ashlee Leone³, Emily Duff³, Alysha Taxter¹, Stacy Ardoin¹ and Vidya Sivaraman⁴, ¹Nationwide Children's Hospital, Columbus, OH, ²Amgen, Columbus, OH, ³Nationwide Children's Hosptial, Columbus, OH, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH
Background/Purpose: Management of Systemic lupus erythematosus (SLE) requires accurate, timely disease activity monitoring for optimal treatment and research. The SLEDAI-2K provides objective clinical and laboratory…
Abstract Number: 1274 • ACR Convergence 2024
Comparing Performance-Based Measures and Self-Reported Questionnaires for Assessment of Executive Function for Youth with Childhood-Onset Systemic Lupus Erythematosus
Tala El Tal¹, Jida Jaffan², Justine Ledochowski³, Louise Boulard⁴, Oscar Mwizerwa², Busisiwe Zapparoli⁵, Sarah Mossad⁶, Victoria Lishak⁷, Ibrahim Mohamed⁸, Joanna Law⁹, Lawrence Ng³, Paris Moaf⁹, Asha Jeyanathan², Adrienne Davis¹⁰, Linda Hiraki³, Deborah Levy³, Ashley Danguecan¹¹ and Andrea Knight¹², ¹The Hospital For Sick Children & Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Neurosciences and Mental Health Program, SickKids Research Institute; The Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Etobicoke, ON, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Kids, Toronto, ON, Canada, ⁸The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹⁰Division of Pediatric Emergency Medicine, Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹¹The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ¹²Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Executive dysfunction is common in childhood-onset systemic lupus erythematosus (cSLE). Comprehensive neuropsychological assessments use both performance-based measures and standardized questionnaires, capturing different cognitive constructs.…
Abstract Number: 1490 • ACR Convergence 2024
Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Vasileios Kyttaris¹, Andrew Concoff², Touba Warsi³, Sepehr Taghavi³, Sudha Kumar³, Stanley Park³, Abigail Patalinghug³, Christine Schleif³, Brittany Partain⁴, Joseph Ahearn⁵, Nicole Wilson⁶, Chau-Ching Liu⁶, Susan Manzi⁶ and Tyler O'Malley⁷, ¹BIDMC, Boston, MA, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Allegheny Health Network, Wexford, PA, ⁶Allegheny Health Network, Pittsburgh, PA, ⁷Exagen, Vista, CA
Background/Purpose: Conventional SLE diagnostic markers lack sensitivity and are biased towards severe disease, resulting in a subset of clinically ambiguous ANA-positive but specific autoantibody-negative patients.…
Abstract Number: 1506 • ACR Convergence 2024
Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery
Chrisanna Dobrowolski¹, Juan Pablo Diaz Martinez², Kathleen Bingham², Michelle Barraclough³, Roberta Kretzmann², Maria Carmela Tartaglia⁴, Lesley Ruttan⁵, May Choi⁶, Simone Appenzeller⁷, Sherief Marzouk², Dennisse Bonilla², Patti Katz⁸, Dorcas Beaton⁹, Robin Green², Joan Wither², Laura Patricia Whittall Garcia², Dafna Gladman¹⁰ and Zahi Touma¹¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²University Health Network, Toronto, ON, Canada, ³The University of Manchester, Manchester, United Kingdom, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, SP, Brazil, ⁸UCSF, San Rafael, CA, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus (SLE) has a well-established association with cognitive impairment (CI) and confers worse quality of life. We previously presented descriptive data regarding the…
Abstract Number: 1522 • ACR Convergence 2024
Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020
Soziema Salia¹, Ufuoma Mamoh², Gilava Hedayati², Joseph Atarere³, Raymond Wadie⁴, Boniface Mensah³, Joan Morny⁵ and Indira Acharya⁶, ¹MedStar Union Memorial Hospital, Towson, MD, ²Medstar Union Memorial Hospital, Baltimore, MD, ³Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, MD, ⁴Department of Internal Medicine, Cayuga Medical Center, Ithaca, NY, ⁵Piedmont Athens Regional Medical Center, Athens, GA, ⁶Medstar Internal Medicine Residency Program, Baltimore, MD
Background/Purpose: Thrombocytopenia is associated with Systemic Lupus Erythematosus (SLE) and occurs at various stages of the disease. It is reported in an estimated 10% to 40% of…
Abstract Number: 1542 • ACR Convergence 2024
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Arezou Khosroshahi¹, Sarah Welsh², Liangwei Wang², David Larson² and Nisha Jain², ¹Emory University, Atlanta, GA, ²Amgen, Inc., Rockville, MD
Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
Abstract Number: 1651 • ACR Convergence 2024
Unlocking the Secrets of Breg Dysfunction in Lupus: Glycosylation Patterns as Therapeutic Targets
Pauline Kerleroux-Trébaol¹, Marie Morel¹, Sandrine Jousse-Joulin², Divi Cornec³, Pierre Pochard¹ and Anne Bordron¹, ¹Université de Bretagne Occidentale, brest, France, ²cavale blanche hospital, brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France
Background/Purpose: The immune system is a complex network of cells preventing the invasion of the organism from external particles. The break in the homeostasis will…
Abstract Number: 1753 • ACR Convergence 2024
A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
Georg Schett¹, Emily Littlejohn², Neil Kramer³, Amit Saxena⁴, Philip Mease⁵, Margrit Wiesendanger⁶, Fabian Müller⁷, Ran Reshef⁸, Paolo Caimi⁹, Mohamad Cherry¹⁰, Jingmei Hsu⁴, Krish Patel¹¹, Jacques Azzi⁶, Susana Falcon¹², Thomas Ly¹³, Ken Ogasawara¹², Sharmila Das¹², Jerill Thorpe¹⁴, Michael Maldonado¹², Giuseppina Stifano¹², Ashley Koegel¹² and Anca Askanase¹⁵, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²Cleveland Clinic, Cleveland, OH, ³Atlantic Medical Group, Atlantic Health System, Morristown, NJ, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, WA, ¹²Bristol Myers Squibb, Princeton, NJ, ¹³Bristol Myers Squibb, San Diego, CA, ¹⁴Bristol Myers Squibb, Seattle, WA, ¹⁵Columbia University Medical Center, New York, NY
Background/Purpose: CD19 is an appealing therapeutic target due to its ubiquitous expression on B cells and plasmablasts, which play a key role in the pathogenesis…
Abstract Number: 1793 • ACR Convergence 2024
SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD
Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
Abstract Number: 1839 • ACR Convergence 2024
PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways
Xuan Fang, Xiangpei Li and Xiaomei Li, The First Affiliated Hospital of University of Science and Technology of China., He Fei, China (People's Republic)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…
Abstract Number: 2049 • ACR Convergence 2024
Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Dongze Wu¹ and Yingzhao jin², ¹Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China (People's Republic), ²Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: There are conflicting findings on the relationship between glucose-lowering drugs and risk of development of immune mediated inflammatory diseases (IMIDs). The study aimed to…
Abstract Number: 2377 • ACR Convergence 2024
Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY
Anitha Ramu¹, Justina Shafik², Maedeh Ashrafi³, Juliann Allen², Kiera Brennan¹ and Noa Schwartz⁴, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Jacobi Medical Center, Bronx, NY, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: Studies have demonstrated that socioeconomic status (SES) significantly influences outcomes of patients with SLE.1 Traditionally, tools such as income, education, occupation, and housing have…
Abstract Number: 2396 • ACR Convergence 2024
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
Anna Korogodina¹, Erin Sundel¹, Yaroslav Markov², Vasileios Kyttaris³, Julianne O'Connell¹ and Suzanne Krishfield¹, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Yale School of Medicine, New Haven, ³BIDMC, Boston, MA
Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…
Abstract Number: 2414 • ACR Convergence 2024
A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
Alma Aveytia Camacho¹, Rakesh Gullapelli², Vineetha Philip³, Soudabeh Daliri¹, Ruba Memon⁴, Helene DiGregorio², Lily Romero Karam², Kanika Monga³, Eleonora Avenatti², Khurram Nasir² and Myriam Guevara¹, ¹Houston Methodist, Houston, TX, ²Houston Methodist Hospital, Houston, TX, ³Houston Methodist Hospital, Sugar Land, TX, ⁴Houston Methodist, Missouri City, TX
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…
Abstract Number: 2430 • ACR Convergence 2024
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Alex S. Powlesland¹, Ioana Cutcutache¹, Andrew Skelton¹, Anthony Shock¹, Matthew Page¹, Eris Bame², Janine Gaiha-Rohrbach², George Stojan³, Ania Skowera¹, Christian Stach⁴ and Thomas Dörner⁵, ¹UCB Pharma, Slough, United Kingdom, ²Biogen Inc., Cambridge, MA, ³UCB Pharma, Atlanta, GA, ⁴UCB Pharma, Monheim am Rheim, Germany, ⁵Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany
Background/Purpose: CD40-CD40L interactions play a pivotal role in systemic lupus erythematosus (SLE) pathogenesis by orchestrating a range of immune and inflammatory responses involving B cells,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].